EA201992886A1 - ACTIVATED ANTIBODIES AGAINST PDL1 AND WAYS OF THEIR APPLICATION - Google Patents
ACTIVATED ANTIBODIES AGAINST PDL1 AND WAYS OF THEIR APPLICATIONInfo
- Publication number
- EA201992886A1 EA201992886A1 EA201992886A EA201992886A EA201992886A1 EA 201992886 A1 EA201992886 A1 EA 201992886A1 EA 201992886 A EA201992886 A EA 201992886A EA 201992886 A EA201992886 A EA 201992886A EA 201992886 A1 EA201992886 A1 EA 201992886A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies against
- ways
- activated antibodies
- application
- pdl1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Изобретение в целом относится к активируемым антителам, которые специфично связываются с PDL1, и к способам получения и применения таких активируемых антител против PDL1 по различным терапевтическим, диагностическим и профилактическим показаниям.The invention generally relates to activated antibodies that specifically bind to PDL1, and to methods for producing and using such activated antibodies against PDL1 for various therapeutic, diagnostic and prophylactic indications.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862657567P | 2018-04-13 | 2018-04-13 | |
PCT/US2018/035508 WO2018222949A1 (en) | 2017-06-01 | 2018-05-31 | Activatable anti-pdl1 antibodies, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992886A1 true EA201992886A1 (en) | 2020-05-12 |
Family
ID=70847628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992886A EA201992886A1 (en) | 2018-04-13 | 2018-05-31 | ACTIVATED ANTIBODIES AGAINST PDL1 AND WAYS OF THEIR APPLICATION |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201992886A1 (en) |
-
2018
- 2018-05-31 EA EA201992886A patent/EA201992886A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792413A1 (en) | ANTIBODIES AGAINST CD71, ACTIVATED ANTIBODIES AGAINST CD71 AND METHODS OF THEIR APPLICATION | |
EA201792414A1 (en) | ANTIBODIES AGAINST CD166, ACTIVATED ANTIBODIES AGAINST CD166 AND METHODS OF THEIR APPLICATION | |
EA201890285A1 (en) | ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
EA201892294A1 (en) | ANTIBODIES AND COMPOSITIONS AGAINST TIM-3 | |
EA201890131A1 (en) | IMMUNOMODULATION AND TREATMENT OF SOLID TUMORS BY ANTIBODIES THAT SPECIFICALLY CONNECT CD38 | |
EA201892362A1 (en) | AGONISTIC ANTIBODIES THAT ARE BINDING HUMAN CD40, AND THEIR OPTIONS | |
EA201890145A1 (en) | ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION | |
EA201692539A1 (en) | ANTIBODIES AND ANTIGENS-BINDING FRAGMENTS, WHICH SPECIFICALLY CONNECT WITH THE PROUCH OF TAU ASSOCIATED WITH MICROTUBULES | |
EA201991720A1 (en) | ANTIBODIES TO ALPHA-SINUCLEIN AND THEIR APPLICATIONS | |
EA202190609A1 (en) | ANTIBODIES AGAINST HLA-G, COMPOSITIONS CONTAINING ANTIBODIES AGAINST HLA-G, AND METHODS OF APPLICATION ANTIBODIES AGAINST HLA-G | |
EA201691541A1 (en) | NEW ANTI-BAFF ANTIBODIES | |
EA201792220A1 (en) | ANTIBODY-MEDIATED NEUTRALIZATION OF THE CHICUNG VIRUS VIRUS | |
EA202091130A1 (en) | LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN | |
EA201892716A1 (en) | Antibody to Coagulation Factor XI | |
EA202091350A1 (en) | BINDING MOLECULES SPECIFICALLY BINDING TO TAU PROTEIN | |
EA201992281A1 (en) | BINDING MOLECULES SPECIFICALLY BINDING TO TAU PROTEIN | |
EA201891299A1 (en) | THERAPEUTIC ANTIBODIES TO CD9 | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
EA202092085A1 (en) | THERAPEUTIC ANTIBODIES AGAINST sPLA2-GIB AND THEIR APPLICATION | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
EA201992318A1 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSTIC AND TREATMENT OF PROSTATE CANCER USING A MOLECULE BINDING PROGASTRIN | |
EA201891528A1 (en) | COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF GASTRIC CANCER | |
EA201992317A1 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSTIC OF LUNG CANCER | |
EA201891529A1 (en) | COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF OVARIAN CANCER | |
EA201992883A1 (en) | ANTIBODIES TO TrkB |